Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cotton Rat RSV Model Launched by Noble Life Sciences and IBT Bioservices

Published: Friday, January 31, 2014
Last Updated: Thursday, January 30, 2014
Bookmark and Share
Cotton rat model for preclinical studies of respiratory syncytial virus therapies and vaccines.

Noble Life Sciences in collaboration with IBT Bioservices has announced a newly optimized cotton rat model for preclinical studies of RSV (respiratory syncytial virus) therapies and vaccines.

The companies jointly developed the model of RSV infection in the cotton rat and demonstrated its use to evaluate the efficacy of test compounds in RSV challenge studies.

Cotton rats are the gold standard for preclinical development of drugs and vaccines for RSV. The cotton rat gained importance for RSV studies because the permissiveness of cotton rats to infection with human RSV surpasses that of mice by more than 100-fold and because the model replicates several characteristic features of the human disease.

Moreover, the predictive quality of the model is so high that treatments for severe disease advanced to clinical trials based on the results of efficacy and safety studies using cotton rats without the need for testing in primates.

Alain Cappeluti, President of Noble Life Sciences, noted, “The optimization of our RSV cotton rat model is the result of a collaborative effort combining the in vivo model expertise of Noble Life Sciences with the vaccine development and virology expertise of IBT Bioservices. Models of infection with other viral pathogens using the cotton rat will be developed. A model of influenza infection is under development in collaboration with IBT Bioservices”.

“We are pleased with our collaboration with Noble Life Sciences in the optimization of this model. Although current treatment options for prevention of RSV disease in high-risk infants are highly effective, the need for cost-effective vaccines or therapeutic options for RSV prevention and treatment in the large population of normal-risk infants and children is great. The cotton rat model of RSV infection will play a pivotal role in the development of such vaccines and therapeutics,” commented Dr. Javad Aman, President and CSO of IBT Bioservices.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Noble Life Sciences Acquires Spring Valley Laboratories
Extends testing services to GLP, large animal and medical device studies.
Thursday, December 04, 2014
Scientific News
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
Paper Filter Can Remove Viruses from Water
A new paper filter can purify water from viruses, even the most difficult and contagious.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Mimicking Evolution to Create Novel Proteins
A study by researchers in the Kuhlman lab offers a new route to design the 'cellular machines' needed to understand and battle diseases.
Antibody Therapy Opens Door to Potential New Treatment for HIV
Researchers at Rockefeller University show how a broadly neutralizing antibody could be used to help fight HIV.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!